News

A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

Allegheny Health Network (AHN) in Pittsburgh, Pennsylvania, has achieved what few health systems have been able to do-offer same-day specialty appointments across its hospital network.

We asked healthcare industry leaders, what apps should managed care executives check out? Here's what they said.

Marathon Pharmaceuticals is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy (MD) after concerns over its $89,000 price tag.

Here’s how experts say the blocked Aetna-Humana and Anthem-Cigna mergers will affect consolidation among payers and providers.

FDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Report highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.

Here’s what a Vizient’s hospital leader survey says about the future of the Affordable Care Act (ACA) and other healthcare policies under the new Administration.

Scott Winiecki, MD, of the FDA Center for Drug Evaluation and Research, shares how the FDA is working to address the opioid epidemic.

SCOTUS nominee Judge Neil Gorsuch could have an impact on healthcare. Here’s how.

How can physicians, already struggling to keep up with mounting regulations and larger patient loads, use PDMPs in more effective and efficient ways?

Commonwealth Fund’s 2016 Biennial Health Insurance Survey found significant improvements in people’s ability to buy health plans on their own after implementation of the ACA insurance reforms.

A new report highlights the top states most affected by repeal of the ACA. Is your state among the top 10?

FDA is warning about rare but serious allergic reactions have from the widely-used skin antiseptic products containing chlorhexidine gluconate.

In the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers.

Several changes and transitions will have a huge impact on health IT in 2017 and in future years.

At Cigna, technology is viewed as a strategic enabler that powers its business strategy-creating closer, more meaningful connections with customers.

Experts share updates on new diabetes medications, and provide an overview of what’s coming.

In order to survive as a managed care organization, it’s important to stay on top of policy changes and reimbursement trends.

Managed Healthcare Executive’s 2017 Technology Survey findings reveal that tools to help consumers estimate the cost of healthcare may be underutilized. Here’s what UnitedHealthcare is doing about that.

Patients need cost information to make the best treatment decisions. But physicians are coming up short.

Three candidates that President Donald Trump is considering for FDA Commissioner are likely to speed drug approvals, analysts say.

A new report has troubling findings for payers, providers, and technology companies. Here are the key takeaways, and reactions from experts.

FDA recently granted accelerated approved for ibrutinib (Imbruvica, Janssen, Pharmacyclics), the first treatment for patients with a certain type of lymphoma.

As Donald Trump was sworn in as the 45th U.S. president, health policy experts share with Managed Healthcare Executive what’s next for healthcare.

As we begin the New Year, healthcare payers have an immediate opportunity to boost member satisfaction.

As the destiny of Obamacare takes center stage, two researchers have proposed the next-generation of HSAs-HDHPs, a new way to design health insurance plans that could win bipartisan support.

The proposed megamerger has been shot down. Find out what it means for healthcare execs.

McKesson Corp., one of the largest distributors of pharmaceuticals, agreed to pay a record civil penalty for alleged violations of the Controlled Substances Act.

Here are 3 reasons why overcoming the “fingerstick” barrier will improve patient outcomes and contribute to reductions in healthcare costs.